Skip to main content
Aditi Bagchi, MD, PhD
Aditi Bagchi, MD, PhD

Aditi Bagchi, MD, PhD

Assistant Member, St. Jude Faculty

Departments

Divisions

Education

Fellowship (Pediatric Neuro-Oncology) – St. Jude Children’s Research Hospital, Memphis, TN
PhD (Cell and Molecular Biology) - Van Andel Research Institute Graduate School, Grand Rapids, MI
Academic Research Fellowship (Pediatric Hematology and Oncology) - Helen DeVos Children’s Hospital/ Van Andel Research Institute, Graduate School Grand Rapids, MI
Fellowship (Pediatric Hematology and Oncology) - Helen DeVos Children’s Hospital/ Van Andel Research Institute Graduate School, Grand Rapids, MI
Residency (Pediatrics) - Brooklyn Hospital Center, Brooklyn, NY   
MBBS – Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, India

Research Interests

  • Infant Type Hemispheric Glioma
  • Rare Brain Tumors of infants and Young Children
  • Molecular and Genomic Characteristics of  Pediatric Brain Tumors (Focus Infants)
  • Medulloblastoma in Infant and Young Children.

Selected Publications

Bagchi A, Dhanda S K, Dunphy P, Sioson E, Robinson GW.  Molecular Classification Improves Therapeutic  Options for Infants and Young Children With Medulloblastoma. J Natl Compr Canc Netw Aug 28;1-9, 2023.  doi: 10.6004/jnccn.2023.7024. PMID: 37663637

Chiang J, Bagchi A (Co-First Author), Li X,  Dhanda S, Huang J, Pinto S, Sioson E, Dalton J, Tatevossian R, Jia S, Partap S, Fisher P, Bowers D, Hassall T, Lu C, Zaldivar-Peraza A, Wright K, Broniscer A, Qaddoumi I, Upadhyaya S, Vinitsky A, Sabin N, Orr B, Klimo P, Boop F, Ashford J, Conklin H, Onar-Thomas A, Zhou X, Ellison D, Gajjar A, Robinson G.  High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse- Results from the SJYC07 trail and institutional experience. Neuro-Oncology July 2023. https://doi.org/10.1093/neuonc/noad130 (online ahead of print)

Bagchi A (First and Corresponding author), Beddows I, Cornelius A, Robinson G, Jewell S. Rare Cases of Medulloblastoma with Hypermutation. Pediatric Blood and Cancer May;5(5):e1521, 2022. doi: 10.1002/cnr2.1521. PMID: 34351088

Bagchi A, Orr B, Campagne O, Dhanda S, Nair S, Tran Q, Gajjar A, Furtado L, Vaislyeva A, Boop F, Stewart C, Robinson G. Lorlatinib in a Child with ALK-Fusion Positive High-Grade Glioma. The New England Journal of Medicine Aug 19;385(8):761-763, 2021. doi: 10.1056/NEJMc2101264. PMID 34407349

Bagchi A (First and Corresponding author), Madaj Z, Engel K, Guan P, Rohrer D, Valley D, Wolfrum E, Feenstra K, Roche N, Hostetter G, Moore H, Jewell S. Impact of Preanalytical Factors on the Measurement of Tumor Tissue Biomarkers Using Immunohistochemistry. J Histochem Cytochem May; 69(5):297-320, 2021. PMID: 33641490

White Y, Bagchi A, Van Jiffle, J Inguva, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ. KRAS insertion mutations are Oncogenic and exhibit distinct Functional properties. Nat Commun 7:10647l, 2016. PMCID: PMC4748120

Bagchi A, Elnawawi A, Sadanandan S. Visual Diagnosis: A 3-1/2-year-old boy with sickle cell beta thalassemia and a groin mass. Pediatr Rev 34(2):e5-8, 2013. PMID:23378618

Last update: September 2023

Close